Upstream Bio (NASDAQ:UPB) Stock Price Down 4.6% – Should You Sell?

Upstream Bio, Inc. (NASDAQ:UPB) shares fell 4.6% during mid-day trading on Wednesday . The stock traded as low as $28.35 and last traded at $29.38. 610,442 shares changed hands during trading, an increase of 0% from the average session volume of 608,064 shares. The stock had previously closed at $30.79.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on UPB shares. Truist Financial assumed coverage on shares of Upstream Bio in a research report on Tuesday, October 14th. They set a “buy” rating and a $47.00 price objective on the stock. Lifesci Capital initiated coverage on shares of Upstream Bio in a research note on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 target price for the company. Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Finally, Evercore ISI started coverage on Upstream Bio in a report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Upstream Bio Trading Down 4.6%

The stock has a market capitalization of $1.59 billion, a PE ratio of -15.63 and a beta of 1.90. The business’s 50 day moving average is $29.26 and its 200 day moving average is $22.86.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.65 million. As a group, analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Hedge Funds Weigh In On Upstream Bio

Hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in Upstream Bio in the fourth quarter worth $29,000. Torren Management LLC purchased a new position in Upstream Bio in the 4th quarter worth about $30,000. BNP Paribas Financial Markets increased its stake in Upstream Bio by 229.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after buying an additional 2,158 shares during the period. Legal & General Group Plc lifted its holdings in Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after buying an additional 1,440 shares in the last quarter. Finally, CWM LLC boosted its position in Upstream Bio by 107.5% in the 2nd quarter. CWM LLC now owns 3,312 shares of the company’s stock valued at $36,000 after buying an additional 1,716 shares during the period.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.